Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide.

"The HemoCue divestiture, along with our sale of OralDNA in December 2012, demonstrates our commitment to refocus our business on diagnostic information services," said Steve Rusckowski , President and Chief Executive Officer of Quest Diagnostics. "We plan to use the proceeds to repurchase approximately $300 million of Quest Diagnostics shares as part of our stock buyback program."

The transaction is expected to be completed in March 2013, subject to customary closing conditions.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2019, June 20). Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million. News-Medical. Retrieved on May 26, 2024 from https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx.

  • MLA

    Quest Diagnostics. "Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million". News-Medical. 26 May 2024. <https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million". News-Medical. https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx. (accessed May 26, 2024).

  • Harvard

    Quest Diagnostics. 2019. Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million. News-Medical, viewed 26 May 2024, https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV